País: Suiza
Idioma: italiano
Fuente: Swissmedic (Swiss Agency for Therapeutic Products)
clofaziminum
Novartis Pharma Schweiz AG
J04BA01
clofaziminum
Capsule
clofaziminum 50 mg, rapae oleum raffinatum, lecithinum, sojae oleum partim hydrogenatum 4.666 mg, sojae oleum hydrogenatum 1.166 mg, cera flava, propylenglycolum, E 321, acidum citricum, Kapselhülle: gelatina, glycerolum (85 per centum), E 172 (rubrum), E 172 (nigrum), E 215 230 µg, ethylvanillinum, propylis parahydroxybenzoas natricus 110 µg, 4-methoxyacetophenonum, aqua purificata, pro capsula.
B
Synthetika
La lebbra
zugelassen
1969-04-24